Table 1.
Study population characteristics of 137 newly referred lung cancer patients in the PACO2 study, Herlev University Hospital, Denmark, 2016–2017.
| Variable | Completed First-Line Treatment ** | |||
|---|---|---|---|---|
| All n (%) |
Yes n (%) |
No n (%) |
p-Value | |
| Sex | ||||
| Men | 71 (52) | 40 (54) | 31 (49) | 0.6 |
| Women | 66 (48) | 34 (46) | 32 (51) | |
| Age at diagnosis (years) | ||||
| ≤65 | 35 (26) | 21 (28) | 14 (22) | 0.5 |
| >65 to <70 | 41 (30) | 24 (32) | 17 (27) | |
| ≥70 to <75 | 39 (28) | 20 (27) | 19 (30) | |
| ≥75 | 22 (16) | 9 (12) | 13 (21) | |
| Mean (SD) | 68.9 (7.4) | 67.9 (7.8) | 70.1 (7.9) | 0.1 |
| Marital status | ||||
| Cohabiting | 96 (70) | 52 (70) | 44 (70) | 1.0 |
| Living alone | 41 (30) | 22 (30) | 19 (30) | |
| Smoking status | ||||
| Never/used to smoke | 107 (79) | 55 (74) | 52 (85) | 0.2 |
| Current smoker | 28 (21) | 19 (26) | 9 (15) | |
| Alcohol | ||||
| 0 units per week | 47 (35) | 26 (36) | 21 (35) | 0.1 |
| >1 to <7/14 units per week | 59 (44) | 28 (38) | 31 (52) | |
| >8/15 units per week | 27 (20) | 19 (26) | 8 (13) | |
| BMI | ||||
| Underweight (<18.5) | 11 (8) | - | - | 0.004 * |
| Normal weight (18.5–24.9) | 60 (44) | 41 (55) | 19 (31) | |
| Overweight (25–29.9) | 45 (33) | 15 (20) | 30 (49) | |
| Obese (≤30) | 19 (14) | 11 (15) | 8 (13) | |
| Education | ||||
| Short | 26 (19) | 13 (18) | 13 (21) | 0.7 |
| Medium | 23 (17) | 14 (19) | 9 (14) | |
| Long | 78 (57) | 40 (55) | 38 (60) | |
| Other | 9 (7) | - | - | |
| Performance score | ||||
| 0 | 71 (53) | 44 (59) | 27 (44) | 0.04 * |
| 1 | 54 (40) | 28 (38) | 26 (43) | |
| 2 | 10 (7) | - | - | |
| Diagnosis | 0.3 | |||
| NSCLC | 116 (85) | 65 (88) | 51 (81) | |
| SCLC | 21 (15) | 9 (12) | 12 (19) | |
| Stage | ||||
| Early/medium | 75 (55) | 41 (55) | 33 (53) | 0.5 |
| Advanced | 62 (45) | 33 (45) | 30 (47) | |
| Comorbidity | ||||
| 0 | 34 (25) | 24 (32) | 10 (16) | 0.08 |
| 1 | 44 (32) | 22 (30) | 22 (35) | |
| ≥2 | 59 (43) | 28 (38) | 31 (49) | |
| Surgery before oncological treatment | ||||
| Yes | 23 (17) | 11 (15) | 12 (19) | 0.5 |
| No | 114 (83) | 63 (85) | 51 (81) | |
| Planned treatment | ||||
| Chemotherapy | 59 (43) | 27 (36) | 32 (51) | 0.2 |
| Radiotherapy Chemoradiotherapy |
4 (3) 63 (46) |
3 (4) 39 (53) |
1 (2) 24 (38) |
|
| Immunotherapy | 11 (8) | 5 (7) | 6 (9) | |
* Significant at the 5% level. ** Consistency between the intended treatment and the actual treatment received. Due to low numbers (>5) few of the categories are collapsed. Missing values are not reported.